Padagis intros generic Uceris

Padagis is introducing budesonide 2 mg rectal foam, the generic of Uceris.

The company has 180 days of competitive generic therapy exclusivity.

Uceris is a prescription corticosteroid medicine used to help get active, mild to moderate ulcerative colitis extending from the rectum to the sigmoid colon under control (induce remission).

[Read more: Teva launches Lialda generic]

Uceris had a market value of approximately $13 million in the 12 months ended March 2023, per IQVIA.

Pam Hoffman, president of Padagis, said, "This launch exemplifies the unique development, clinical and manufacturing technologies native to Padagis. Further, the CGT exclusivity awarded to the Padagis ANDA highlights our ability to successfully navigate the regulatory environment and commercialize this important product for our customers and patients."